- Biondvax Pharmaceuticals press release (NASDAQ:BVXV): Q1 GAAP EPS of $0.00 beats by $0.73.
- As of March 31, 2023, BiondVax had cash and cash equivalents of $10.9 million as compared to $14.2 million as of December 31, 2022. The decrease in cash from December 31, 2022, to March 31, 2023, was primarily due to net cash used in operating activities of $3.1 million.
Biondvax Pharmaceuticals GAAP EPS of $0.00 beats by $0.73
Recommended For You
More Trending News
About SCNI Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SCNI | - | - |
Scinai Immunotherapeutics Ltd. |